Company: CSTL
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001447362-25-000069
Chunk: 13

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-05-05
Form: 10-Q
Item: Item 1
Chunk 13
---
 related recognition of revenue in current period for tests delivered in prior periods due to the release of the constraint on variable consideration. Because our contracts with customers have an expected duration of one year or less, we have elected the practical expedient in ASC 606 to not disclose information about our remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expenses as incurred due to the short duration of our contracts. Contract balances consisted solely of accounts receivable (both current and noncurrent) as of March 31, 2025 and December 31, 2024.Disaggregation of RevenuesThe table below provides the disaggregation of revenue by type (in thousands):Three Months EndedMarch 31,20252024Dermatologic(1)$62,962 $59,334 Non-Dermatologic(2)25,026 13,640 Total net revenues$87,988 $72,974 (1)Consists of DecisionDx-Melanoma, DecisionDx-SCC and our Diagnostic Gene Expression Profile offering.(2)Consists of TissueCypher, DecisionDx-UM and IDgenetix. 

11

Table of ContentsCASTLE BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(UNAUDITED)

We have presented disaggregated net revenues included in our single reportable segment in the table above. The characteristics for each test in our single segment are similar, with each test having a single performance obligation. Our CODM is the single individual responsible for managing our segment and reviews consolidated results and budgets in assessing performance and in allocating resources. See Note 14 for additional information about our reportable segment.Payor ConcentrationWe rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our tests.Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances were as follows: Percentage of Revenues Three Months EndedMarch 31,Percentage of Accounts Receivable (current) as ofPercentage of Accounts Receivable (noncurrent) as of 20252024March 31, 2025December 31, 2024March 31, 2025December 31, 2024Medicare47 %49 %21 %18 %**Payor A15 %14 %16